Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 8314 results

  1. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

  2. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

    Topic prioritisation

  3. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]

    In development Reference number: GID-TA11675 Expected publication date: TBC

  4. Artificial Intelligence in MRI for prostate cancer diagnosis

    Awaiting development Reference number: GID-HTE10089 Expected publication date: TBC

  5. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  06 May 2026

  6. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

    In development Reference number: GID-TA11742 Expected publication date: TBC

  7. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

    In development Reference number: GID-TA11649 Expected publication date: TBC

  8. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  25 February 2026

  9. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  04 March 2026

  10. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development Reference number: GID-TA11340 Expected publication date: TBC

  11. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development Reference number: GID-TA10981 Expected publication date:  08 April 2026

  12. Polycystic ovary syndrome: assessment and management

    In development Reference number: GID-NG10436 Expected publication date:  03 November 2026

  13. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development Reference number: GID-TA10279 Expected publication date: TBC

  14. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

    In development Reference number: GID-TA10311 Expected publication date: TBC

  15. In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.